Search for content, post, videos
Advertisement

Biovian invests over 50 million EUR in manufacturing facility

CDMO Biovian has announced a major investment to expand its manufacturing facility in Turku, Finland.

The new facility will cover an area of 6,400 sqm and house cutting-edge equipment and advanced technologies to support the development, manufacturing, and testing of ATMP (Advanced Therapy Medicinal Products), such as adenoviral and AAV (adeno-associated viral) therapies. It will also feature dedicated Class A to D cleanroom areas for bulk drug substances as well as final drug product manufacture. The expanded facility will adhere to current good manufacturing practices (cGMP) and fulfilling both EU and US GMP requirements ensuring the delivery of safe, reliable, and compliant biopharmaceutical products, describes the company.

The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland and most of all provide vital therapies to patients suffering from today’s untreatable diseases.”

“The new manufacturing facility will not only strengthen Biovian’s position as a key player in the CDMO sector, but also contribute to the growth of the biopharmaceutical industry in Finland and most of all provide vital therapies to patients suffering from today’s untreatable diseases. Biovian aims to facilitate swift drug development and delivery, reducing time-to-market for its customers, all while creating an enjoyable experience. The new manufacturing facility will increase viral vector capacity, but it will also increase our capacity and flexibility in microbial protein. When the new site is up and running, our existing capacity will be transformed to new microbial protein suites. Thus, both microbial and viral vector customers will benefit from this expansion,” says Antti Nieminen, CEO of Biovian.

Completed in December 2024

Together with Biovian’s existing manufacturing facility, the new premises will increase the total area up to 11 500 sqm. The additional space complements Biovian’s existing manufacturing facilities in the area and will enable Biovian to undertake larger-scale viral vector as well as microbial protein projects and concurrent manufacturing campaigns by increasing overall production capacity and flexibility.

The investment is expected to create 100 job opportunities in the region.”

The expansion project is expected to be completed in December 2024, with the new facility fully operational by 2025. The investment is expected to create 100 job opportunities in the region, adding to Biovian’s already approximately 200 strong team, the company states.

Photo of Antti Nieminen: Biovian

Advertisement